These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 34433362)

  • 41. New developments in inhaler devices within pharmaceutical companies: A systematic review of the impact on clinical outcomes and patient preferences.
    Ninane V; Vandevoorde J; Cataldo D; Derom E; Liistro G; Munghen E; Peché R; Schlesser M; Verleden G; Vincken W
    Respir Med; 2015 Nov; 109(11):1430-8. PubMed ID: 26439177
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Tiotropium Respimat Soft Mist Inhaler versus HandiHaler to improve sleeping oxygen saturation and sleep quality in COPD.
    Bouloukaki I; Tzanakis N; Mermigkis C; Giannadaki K; Moniaki V; Mauroudi E; Michelakis S; Schiza SE
    Sleep Breath; 2016 May; 20(2):605-12. PubMed ID: 26407963
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Shared Decision-Making Facilitates Inhaler Choice in Patients with Newly-Diagnosed Chronic Obstructive Pulmonary Disease: A Multicenter Prospective Study.
    Hsiao YH; Tseng CM; Sheu CC; Wang HY; Ko HK; Su KC; Tao CW; Tsai MJ; Chen YF
    Int J Chron Obstruct Pulmon Dis; 2022; 17():2067-2078. PubMed ID: 36081765
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Low incidence of paradoxical bronchoconstriction with bronchodilator drugs administered by Respimat Soft Mist inhaler: results of phase II single-dose crossover studies.
    Koehler D; Pavia D; Dewberry H; Hodder R
    Respiration; 2004; 71(5):469-76. PubMed ID: 15467324
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The Respimat
    Iwanaga T; Tohda Y; Nakamura S; Suga Y
    Clin Drug Investig; 2019 Nov; 39(11):1021-1030. PubMed ID: 31377981
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Requirements, Strengths and Weaknesses of Inhaler Devices for COPD Patients from the Expert Prescribers' Point of View: Results of the EPOCA Delphi Consensus.
    García-Río F; Soler-Cataluña JJ; Alcazar B; Viejo JL; Miravitlles M
    COPD; 2017 Dec; 14(6):573-580. PubMed ID: 28891722
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Impact of tiotropium + olodaterol on physical functioning in COPD: results of an open-label observational study.
    Sauer R; Hänsel M; Buhl R; Rubin RA; Frey M; Glaab T
    Int J Chron Obstruct Pulmon Dis; 2016; 11():891-8. PubMed ID: 27217742
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Lack of paradoxical bronchoconstriction after administration of tiotropium via Respimat® Soft Mist™ Inhaler in COPD.
    Hodder R; Pavia D; Lee A; Bateman E
    Int J Chron Obstruct Pulmon Dis; 2011; 6():245-51. PubMed ID: 21814460
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A Handling Study to Assess Use of the Respimat(®) Soft Mist™ Inhaler in Children Under 5 Years Old.
    Kamin W; Frank M; Kattenbeck S; Moroni-Zentgraf P; Wachtel H; Zielen S
    J Aerosol Med Pulm Drug Deliv; 2015 Oct; 28(5):372-81. PubMed ID: 25844687
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A review of the development of Respimat Soft Mist Inhaler.
    Dalby R; Spallek M; Voshaar T
    Int J Pharm; 2004 Sep; 283(1-2):1-9. PubMed ID: 15363496
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparative mortality risk of tiotropium administered via handihaler or respimat in COPD patients: are they equivalent?
    Mathioudakis AG; Chatzimavridou-Grigoriadou V; Evangelopoulou E; Mathioudakis GA; Siafakas NM
    Pulm Pharmacol Ther; 2014 Aug; 28(2):91-7. PubMed ID: 24846455
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Determinants and Differences in Satisfaction with the Inhaler Among Patients with Asthma or COPD.
    Plaza V; Giner J; Curto E; Alonso-Ortiz MB; Orue MI; Vega JM; Cosío BG;
    J Allergy Clin Immunol Pract; 2020 Feb; 8(2):645-653. PubMed ID: 31586668
    [TBL] [Abstract][Full Text] [Related]  

  • 53. COPD patient satisfaction with ipratropium bromide/albuterol delivered via Respimat: a randomized, controlled study.
    Ferguson GT; Ghafouri M; Dai L; Dunn LJ
    Int J Chron Obstruct Pulmon Dis; 2013; 8():139-50. PubMed ID: 23658479
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Patient preference for chronic obstructive pulmonary disease (COPD) treatment inhalers: a discrete choice experiment in France.
    Chouaid C; Germain N; De Pouvourville G; Aballéa S; Korchagina D; Baldwin M; Le Lay K; Luciani L; Toumi M; Devillier P
    Curr Med Res Opin; 2019 May; 35(5):785-792. PubMed ID: 30681007
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Preferences and Inhalation Techniques for Inhaler Devices Used by Patients with Chronic Obstructive Pulmonary Disease.
    Bournival R; Coutu R; Goettel N; Yang CD; Cantin-Lafleur A; Lemieux C; Lévesque AM; Patenaude-Monette JF; Roy FO; Blais L; Arbour F; Fillion A; Beauchesne MF
    J Aerosol Med Pulm Drug Deliv; 2018 Aug; 31(4):237-247. PubMed ID: 29206566
    [TBL] [Abstract][Full Text] [Related]  

  • 56. An in vitro study to assess facial and ocular deposition from Respimat Soft Mist inhaler.
    Newman SP; Steed KP; Reader SJ; Pavia D; Sohal AK
    J Aerosol Med; 2007; 20(1):7-12. PubMed ID: 17388748
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Improved delivery of fenoterol plus ipratropium bromide using Respimat compared with a conventional metered dose inhaler.
    Goldberg J; Freund E; Beckers B; Hinzmann R
    Eur Respir J; 2001 Feb; 17(2):225-32. PubMed ID: 11334124
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparison of the aerosol velocity and spray duration of Respimat Soft Mist inhaler and pressurized metered dose inhalers.
    Hochrainer D; Hölz H; Kreher C; Scaffidi L; Spallek M; Wachtel H
    J Aerosol Med; 2005; 18(3):273-82. PubMed ID: 16181002
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pressurised metered-dose inhalers versus all other hand-held inhalers devices to deliver bronchodilators for chronic obstructive pulmonary disease.
    Ram FS; Brocklebank DM; Muers M; Wright J; Jones PW
    Cochrane Database Syst Rev; 2002; 2002(1):CD002170. PubMed ID: 11869627
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The economic impact of educational training assessed by the Handling Questionnaire with three inhalation devices in asthma and Chronic Obstructive Pulmonary Disease patients.
    Dal Negro RW; Povero M
    Clinicoecon Outcomes Res; 2016; 8():171-6. PubMed ID: 27274291
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.